Telix Pharmaceuticals’ (TLX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a report published on Wednesday,Benzinga reports. The firm currently has a $22.00 price target on the stock.

Other analysts have also issued reports about the company. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $11.45 on Wednesday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The stock’s fifty day simple moving average is $11.35 and its 200 day simple moving average is $10.47.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TLX. XY Capital Ltd raised its holdings in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000. Bank of America Corp DE boosted its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares during the period. Finally, Private Advisor Group LLC increased its position in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.